- Home
- CVKD vs ABTS Comparison
CVKD vs ABTS Comparison
Compare CVKD & ABTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | ABTS |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.2M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVKD | ABTS |
|---|---|---|
| Price | $1.08 | $1.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 59.6K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.76 |
| 52 Week High | $14.64 | $10.86 |
Technical Indicators
Market Signals| Indicator | CVKD | ABTS |
|---|---|---|
| Relative Strength Index (RSI) | 22.65 | 54.29 |
| Support Level | N/A | $1.00 |
| Resistance Level | $2.23 | $1.56 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 5.43 | 50.43 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
About ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.